Abstract
Angiogenesis is required for invasive tumor growth and metastasis and constitutes an important point in the control of cancer progression. Its inhibition may be a valuable approach to cancer therapy. Antiangiogenic agents are designed to attack the tumor vasculature and cut off the tumors supply of nutrients. Systemic blockade of angiogenesis has been recently approved for the treatment of several types of human cancers. Antiangiogenic therapy presents various advantages as compared to conventional treatment. Vascular endothelial growth factor (VEGF) is considered to be one of the most important regulators of angiogenesis and a key target in anticancer treatment. VEGF binding to its receptor (VEGFR) leads to cell proliferation and new vascular formation by tyrosine kinase (TK) pathway. VEGF/VEGFR pathway is becoming attractive target for anticancer drug design. It is believed to be important in the control of angiogenesis. Antiangiogenic therapy based on inhibition of VEGFR was reported to be powerful clinical strategies. In this review, the authors describe the existing literature regarding VEGFR inhibitors in the last few years. We attempt to cover all essential publications on the medicinal chemistry in terms of chemical structure, pharmacological profile and structure-activity relationships.
Keywords: Antiangiogenic agents, angiogenesis, VEGFR, tyrosine kinase, anticancer, Vascular endothelial growth factor, tumor, Placenta Growth Factor, DFG, Mab
Mini-Reviews in Medicinal Chemistry
Title: Recent Advances in Antiangiogenic Agents with VEGFR as Target
Volume: 11 Issue: 11
Author(s): J. Zhang, Y. Shan, X. Pan and L. He
Affiliation:
Keywords: Antiangiogenic agents, angiogenesis, VEGFR, tyrosine kinase, anticancer, Vascular endothelial growth factor, tumor, Placenta Growth Factor, DFG, Mab
Abstract: Angiogenesis is required for invasive tumor growth and metastasis and constitutes an important point in the control of cancer progression. Its inhibition may be a valuable approach to cancer therapy. Antiangiogenic agents are designed to attack the tumor vasculature and cut off the tumors supply of nutrients. Systemic blockade of angiogenesis has been recently approved for the treatment of several types of human cancers. Antiangiogenic therapy presents various advantages as compared to conventional treatment. Vascular endothelial growth factor (VEGF) is considered to be one of the most important regulators of angiogenesis and a key target in anticancer treatment. VEGF binding to its receptor (VEGFR) leads to cell proliferation and new vascular formation by tyrosine kinase (TK) pathway. VEGF/VEGFR pathway is becoming attractive target for anticancer drug design. It is believed to be important in the control of angiogenesis. Antiangiogenic therapy based on inhibition of VEGFR was reported to be powerful clinical strategies. In this review, the authors describe the existing literature regarding VEGFR inhibitors in the last few years. We attempt to cover all essential publications on the medicinal chemistry in terms of chemical structure, pharmacological profile and structure-activity relationships.
Export Options
About this article
Cite this article as:
Zhang J., Shan Y., Pan X. and He L., Recent Advances in Antiangiogenic Agents with VEGFR as Target, Mini-Reviews in Medicinal Chemistry 2011; 11 (11) . https://dx.doi.org/10.2174/138955711797068355
DOI https://dx.doi.org/10.2174/138955711797068355 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Characterization of Hypersecreting or Non-Hypersecreting Adrenal Adenomas: Comparison between Iodine-131 Nor-Cholesterol Scintigraphy and Magnetic Resonance Imaging
Current Radiopharmaceuticals Labeling Polyamidoamine (PAMAM) Dendrimers with Technetium-99m via Hydrazinonicotinamide (HYNIC)
Current Radiopharmaceuticals Molecular Basis for Designing Selective Modulators of Retinoic Acid Receptor Transcriptional Activities
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Betulinic Acid as a Potent and Complex Antitumor Phytochemical: A Minireview
Anti-Cancer Agents in Medicinal Chemistry Recent Clinical Evidence in Bisphosphonate-related Osteomyelitis of the Jaw: Focus on Risk, Prevention and Treatment
Reviews on Recent Clinical Trials Malignant Mesothelioma: Biology, Diagnosis and Therapeutic Approaches
Current Molecular Pharmacology Estrogen Receptor Neurobiology and its Potential for Translation into Broad Spectrum Therapeutics for CNS Disorders
Current Molecular Pharmacology DNA Instability at Chromosomal Fragile Sites in Cancer
Current Genomics Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Immune Therapy in Pancreatic Cancer: Now and the Future?
Reviews on Recent Clinical Trials Endocrine Disruptors and Human Health
Mini-Reviews in Medicinal Chemistry Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations
Current Pharmaceutical Design Emerging Risk Factors for Cerebrovascular Disease
Current Drug Targets Novel Aspects in the Pathogenesis of Nonalcoholic Steatohepatitis
Current Molecular Medicine Anti-Angiogenic and Anti-Inflammatory Effects of Statins: Relevance to Anti-Cancer Therapy
Current Cancer Drug Targets Folic Acid Conjugated Chitosan Nanoparticles for Tumor Targeting of Therapeutic and Imaging Agents
Pharmaceutical Nanotechnology PET Imaging for Gene & Cell Therapy
Current Gene Therapy Molecular Chaperone-Mediated Nuclear Protein Dynamics
Current Protein & Peptide Science Targeting Strategies to Modulate the NF-κB and JNK Signal Transduction Network
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Molecular Targets and Angiogenesis in Renal Cell Carcinoma, A Multitarget Approach: Mini Review
Current Drug Targets